Long-term effects of oxandrolone treatment in childhood on neurocognition, wellbeing and social-emotional functioning in young adults with Turner syndrome

Program: Abstracts - Orals, Featured Poster Presentations, and Posters
Session: SAT 498-531-Female Repro Endocrinology & Case Reports
Saturday, June 15, 2013: 1:45 PM-3:45 PM
Expo Halls ABC (Moscone Center)

Poster Board SAT-502
Kim Freriks*1, Chris M Verhaak2, Theo CJ Sas3, Leonie A Menke4, Jan M Wit5, Barto J Otten2, Sabine MPF De Muinck Keizer-Schrama6, Dominique FCM Smeets2, Romana T Netea-Maier1, Ad R.M.M. Hermus1, Roy PC Kessels7 and Henri JLM Timmers8
1Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 2Radboud University Nijmegen Medical Centre, Nijmegen, 3Albert Schweitzer Hospital, Dordrecht, 4Haga Hospital, The Hague, 5Leiden University Medical Centre, Leiden, 6Erasmus Medical Centre, Rotterdam, 7Radboud University Nijmegen, Nijmegen, 8Radboud University Nijmegen Medical Center, Nijmegen, Netherlands

Turner syndrome (TS) is the result of (partial) absence of one sex chromosome. Besides short stature, gonadal dysgenesis and other physical aspects, TS women have typical psychological features. In the current study, we investigated long-term psychological functioning after oxandrolone (Ox) therapy during childhood in adults with TS.


During the initial study, girls were treated with growth hormone (GH) combined with placebo (Pl), Ox 0.03 mg/kg/day, or Ox 0.06mg/kg/day from the age of eight, and estrogen from the age of twelve. Sixty-eight women participated in the current double-blinded follow-up study (mean age 24.0y, mean time since stopping GH 8.7y, mean time of Ox/Pl use 4.9y). The psychological assessments were categorized in wellbeing and quality of life, social and emotional functioning, neurocognition and intelligence, and psychosexual wellbeing.


Compared to Pl, women treated with Ox had slightly lower scores on quality of life, more feelings of distress, slightly higher anxiety levels and a somewhat lower disease acceptance rate. However, these results were not consistent for all subscales. In addition, Ox-treated patients performed worse on emotion recognition, without effect on interpersonal behavior. We found no effects of Ox on neurocognition, intelligence and psychosexual wellbeing.


We show that TS women previously treated with Ox have a somewhat reduced level of well-being and quality of life compared to Pl treated women. Ox was associated with a slightly reduced emotion perception without consequences on social functioning. No late effects on intelligence, executive function and psychosexual wellbeing are present. Consideration of potential psychological effects is essential when treating TS girls with Ox.

Nothing to Disclose: KF, CMV, TCS, LAM, JMW, BJO, SMD, DFS, RTN, ARMMH, RPK, HJT

*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm

Sources of Research Support: Pfizer